Drug/Device Combo Safety Monitoring Is Cooperation Barrier, Pfizer Says
Executive Summary
Concerns about how to conduct postmarket safety surveillance are major impediments to the development of cross-labeled combination products, Pfizer Medical & Development Sciences Executive Director David Eveleth said